Should minimal residual disease negativity not be the end point of myeloma therapy?
Author:
Affiliation:
1. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/1/8/522/878229/advances000109.pdf
Reference22 articles.
1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma;Rajkumar;Lancet Oncol,2014
2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016
3. Multiple myeloma;Palumbo;N Engl J Med,2011
4. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation;Palumbo;J Clin Oncol,2014
5. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma;Stewart;N Engl J Med,2015
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma;Bone Marrow Transplantation;2020-01-28
2. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives;Frontiers in Oncology;2019-08-20
3. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma;Drugs;2017-11-10
4. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy;Journal of Clinical Oncology;2017-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3